Healthcare is one of the few sectors that can hold up in a recession while still delivering strong compounding over long bull markets. But screening for healthcare stocks without a framework is a fast way to end up holding a biotech lottery ticket instead of a quality compounder. The filters that work for industrials or consumer discretionary often fail here — you need metrics that account for pipeline risk, regulatory exposure, and the unusual economics of drug pricing.
Why Healthcare Screening Is Different
Healthcare breaks into five distinct sub-sectors: pharmaceuticals, biotechs, medical devices, managed care (health insurers), and healthcare services. Each has its own earnings profile and valuation logic. A biotech burning cash pre-revenue is not comparable to a mature managed care company with 4% operating margins. The single biggest mistake screeners make is applying the same P/E threshold across all five. Pharma majors typically trade at 12–20× earnings; high-growth medtech can command 35–50×; pre-profit biotechs are valued on pipeline milestones, not earnings at all. Start every healthcare screen by narrowing to a sub-sector first.
Core Filters for Profitable Healthcare Companies
For profitable healthcare names — pharma, medtech, managed care — these thresholds have historically surfaced quality at a reasonable price:
- Gross margin > 50%: Healthcare should have pricing power. Gross margins below 50% usually mean a commoditized generic manufacturer or a thin-margin services business. Medtech leaders run 60–70%; pharma majors often hit 75%+.
- Operating margin > 15%: R&D-heavy companies invest heavily, but operational efficiency still matters. Screens below 15% often flag companies that can't convert their intellectual property into earnings.
- Return on Invested Capital (ROIC) > 12%: This is the cleanest way to separate true healthcare compounders from capital destroyers. Companies with durable drug franchises or medical device lock-in consistently post ROIC above 15%. Below 10% is a red flag.
- Debt-to-equity < 1.5: Healthcare companies carry debt for acquisitions — that's normal. But above 1.5× equity, you're taking on balance sheet risk that can compound badly when a drug loses patent protection or a trial fails.
Revenue Growth and R&D as a Signal
In healthcare, R&D spend is simultaneously a cost and a quality signal. Companies reinvesting 15–20% of revenue into R&D and still generating positive free cash flow are demonstrating operational leverage. Screen for revenue growth > 8% CAGR over 3 years combined with positive free cash flow yield. This combination filters out companies growing only by acquisition or accounting manipulation. Watch for R&D as a percentage of revenue: under 8% in pharma often means a company is milking an aging portfolio with no pipeline refill; above 25% with no near-term revenue may signal excessive pipeline dependence.
Valuation: P/E Works Poorly Here — Use PEG and EV/EBITDA
Because healthcare earnings are lumpy (a single drug approval or patent expiry moves the P&L dramatically), trailing P/E is a weak filter. Two better approaches:
- PEG ratio < 1.5: Divides P/E by expected earnings growth. A company at 25× earnings growing at 20% annually (PEG = 1.25) is cheaper than a company at 18× growing at 5% (PEG = 3.6). In healthcare, PEG under 1.5 typically signals genuine value relative to growth.
- EV/EBITDA < 18× for large-cap healthcare: Medical devices and managed care are more capital-intensive than software, so EV/EBITDA is more meaningful than P/E. Large-cap pharma averages 12–16× in normal markets; medtech 18–25×. Screening below sector averages surfaces potential value before the market reprices.
Defensive Characteristics to Screen For
Healthcare's defensive appeal rests on demand inelasticity — people don't stop taking medication in recessions. But not all healthcare stocks are equally defensive. To isolate the most recession-resistant names, add these filters:
- Dividend payout ratio 20–60%: Companies paying dividends in this range have committed to returning capital without over-leveraging the payout.
- Current ratio > 1.5: Short-term liquidity matters when clinical trials run over budget or regulatory timelines slip.
- Revenue concentration: A company with one drug representing 70%+ of revenue is not defensive — it's binary. Check 10-K disclosures for product concentration risk.
Combining revenue growth with defensive balance sheet metrics helps you find healthcare companies that can compound in bull markets and hold their value when broader indices correct by 20–30%.
Putting It Together on DeltaScreener
The most efficient way to run a healthcare screen is to start with sector filter → sub-sector → then layer fundamentals. On DeltaScreener's screener, you can set gross margin, operating margin, revenue growth, ROIC, and valuation multiples simultaneously and scan the full US market in seconds. The screener updates data regularly so your results reflect current financials, not stale annual figures. Run the screen, sort by ROIC descending, and cross-check the top 10–15 names against their pipeline or product concentration before building a position. Healthcare rewards patience and penalizes shortcuts — but a disciplined screen gets you into the right names at the right valuations.